珠海市藤栢医药

Zhuhai Tengbai Pharmaceutical is a clinical-stage biotechnology company based in Zhuhai, China, dedicated to the discovery and development of novel small molecule therapeutics. The company primarily focuses on the NLRP3 inflammasome pathway, a critical driver of inflammation involved in various chronic and autoimmune diseases. Its lead candidate, TB-001, is a potent and selective NLRP3 inhibitor currently in Phase 1 clinical development for the treatment of gouty arthritis. Beyond its lead program, Tengbai is exploring the application of its technology in metabolic disorders, neurodegeneration, and oncology. The firm is led by a team of experienced scientists with a strong track record in medicinal chemistry and drug optimization. Tengbai aims to address significant unmet medical needs by developing best-in-class treatments for inflammatory conditions.